A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
第一作者:
M R,Hall
第一单位:
Mount Vernon Cancer Centre, Northwood, UK. Electronic address: Marcia.hall@nhs.net.
作者:
医学主题词
投药, 口服(Administration, Oral);老年人(Aged);血管生成抑制剂(Angiogenesis Inhibitors);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环磷酰胺(Cyclophosphamide);输卵管肿瘤(Fallopian Tube Neoplasms);女(雌)性(Female);人类(Humans);吲哚类(Indoles);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);卵巢肿瘤(Ovarian Neoplasms);腹膜肿瘤(Peritoneal Neoplasms);生活质量(Quality of Life)
DOI
10.1016/j.ygyno.2020.09.048
PMID
33077258
发布时间
2023-11-15
- 浏览0
Gynecologic oncology
692-698页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



